Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TVF Communications

- PMLiVE

BeiGene’s tislelizumab receives CHMP recommendation for non-small cell lung cancer

Lung cancer is the second most common type of cancer and the leading cause of cancer-related death globally

- PMLiVE

ICR study reveals AstraZeneca’s ceralasertib sensitises tumours to immunotherapy

Results showed that the drug stopped tumour growth in more than half of patients

- PMLiVE

VML Health announces trio of appointments to creative leadership team

Mel Routhier, Natxo Diaz and Khalid Latif will lead a specialist creative team spanning three continents

- PMLiVE

Valuable research insights to steer pharma’s HCP engagement impact

By Michelle Kelly

- PMLiVE

Committing to diversity: the key to pharmaceutical supply chain resilience

By Carolyn Riegel

- PMLiVE

How brands can rise to meet consumers’ high self-care expectations

With ‘The Great Deceleration’ – a move towards slow living, and a focus on improving mental wellbeing being two predicted trends this year, does this open the door to a...

Fox&Cat

- PMLiVE

Kristin Ludwig joins BOLDSCIENCE’s leadership team as SVP to lead new BOLDADVOCACY division

BOLDADVOCACY expands BOLDSCIENCE’s strategic medical communications services into patient advocacy and engagement

BOLDSCIENCE

- PMLiVE

Novo Nordisk and Neomorph enter molecular glue degrader partnership worth over $1.4bn

The companies will work on therapies for cardiometabolic and rare diseases

- PMLiVE

AstraZeneca’s Voydeya receives CHMP recommendation for rare blood disease PNH

Up to 20% of PNH patients treated with a C5 inhibitor experience clinically significant extravascular haemolysis

- PMLiVE

Novartis and Genentech’s Xolair shown to significantly reduce allergic reactions to food

Food-related anaphylaxis results in 30,000 emergency room visits in the US each year

- PMLiVE

Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

The blood cancer affects approximately 160,000 people worldwide

- PMLiVE

Researchers develop screening tool to investigate mechanisms behind multiple diseases

The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links